Perjeta, formally called pertuzumab, is a crucial advancement in addressing HER2-positive mammary cancer. The medication works by targeting a particular pathway which helps cancer cells grow . In contrast to some other HER2-targeted therapies, pertuzumab avoids directly block the HER2 receptor it